Introduction
Chimeric antigen receptor (CAR) T cell therapy has shown great promise as one of several emerging immunotherapies to effectively treat cancers in the clinic [1] [2] [3] [4] [5] [6] . CARs are created by fusing an extracellular domain, such as a single chain fragment variable (scFv), to a transmembrane domain, followed by a costimulatory signaling molecule such as 4-1BB or CD28, and a cytoplasmic domain of CD3ζ chain to provide a primary T cell activation signal. CARs allow manipulation of T cell function and activity through the synthetic receptor, while bypassing T-cell-specific activation checkpoints, such as major histocompatibility recognition and priming by antigen presenting cells to activate antigen-specific T cells.
Previous studies have focused on elucidating the effects of the costimulatory domains and how they affect CAR T cell function [7] [8] [9] [10] [11] [12] [13] . Further innovation within the field has broadened the scope of designing CAR T cells to improve safety or expand their function. One aspect of these new advancements is the co-expression of secondary immunoregulatory genes with the CAR to direct T cell function [14] [15] [16] . For example, CAR T cells co-expressing IL-12 have shown the ability to release IL-12 at the tumor site, improving antitumor activity [17] [18] [19] .
T-box expressed in T cells (T-bet) is a transcription factor widely known as the master regulator for differentiating CD4
+ T helper cells to a T helper 1 (Th1)
phenotype [20] . Th1 T cells are effective mediators of antitumor activity and have been correlated with improved prognosis in patients [21, 22] . T-bet functions to upregulate Th1-specific genes and proinflammatory pathways while suppressing those involved in differentiation of CD4 + T cells into Th2 cells [23] [24] [25] [26] [27] [28] .
T-bet modulates these pathways through its T-box DNA-binding domain, regulating genes such as IFN-γ, or through complexing with other partner proteins through its transactivation domains, such as NF-ΚB or GATA-3 [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] .
In this study, we investigated whether the overexpression of T-bet can be used to induce a Th1-like phenotype and functional response by CD4 + T cells co-expressing a CAR specific for B7H6. B7H6 has been reported as a tumorrestricted ligand expressed on many different tumors [38] [39] [40] . The studies demonstrated that CD4 + T cells expressing a B7H6-specific CAR and overexpressing T-bet can induce a potent antitumor response and promote long-term survival in vivo.
Materials and methods

Mice
Female C57BL/6 (B6) mice were purchased from either the National Cancer Institute or Jackson Laboratories. Mice were 7-12 weeks old at the start of experiments. All animal experiments and procedures were ethically conducted under the approval of Dartmouth College's Institution Animal Care and Use Committee.
Cell lines and cell culture
The murine cell lines RMA-B7H6 and B16F10-B7H6 are murine cell lines engineered to express human B7H6 and were previously generated [40] . heat-inactive fetal bovine serum, 10 mM HEPES, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 100 U/mL penicillin, 100 μg/mL streptomycin, and 50 μM of 2-ME. B16F10 and B16F10-B7H6 were cultured in complete Dulbecco's modified eagle's (DMEM) media, made with DMEM with a high glucose concentration (4.5 g/L) supplemented with the same supplements as the complete RPMI 1640 media.
Construction of B7H6-specific CAR T-bet constructs
The B7H6-specific CAR was constructed previously [40] . The mouse T-bet gene was synthesized by Genewiz (Southplainfield, NJ, USA). T-bet (STOP) was generated by mutating nucleotide 214G→T. T-bet (ΔTBOX) was generated by deletion of T-bet nucleotides 403-978. The B7H6-specific CAR was fused to a furin cleavage site SGSG-T2A sequence followed by T-bet or other T-bet variants (T-bet (STOP) or T-bet (ΔTBOX)), and were cloned into the pFBneo retroviral vector. All PCR reactions were carried out by using high-fidelity DNA polymerase Phusion (New England BioLabs, Ipswich, MA, USA) and DNA primers purchased from IDT DNA (Coralville, IA).
Retrovirus production
Eighteen hours (h) before transfection, 2.5 × 10 6 293T cells were plated on a 10-cm plate in 10 mL of complete DMEM media to produce ecotropic virus. Cells were then transfected with 20 μg of a B7H6-specific CAR/T-bet plasmid and 10 μg of ψeco packaging plasmid using X-fect (Clontech), according to the manufacturer's protocol. Forty-eight hours post transfection, media was harvested and filtered through a 0.45 μM filter before storage at −80°C. To generate stable packaging cell lines, ecotropic virus made from 293T cells was used to infect PT67 cells followed by G418 selection (1 mg/mL) for 7 days. To make stable cell lines that produce ecotropic virus, dualtropic virus generated from PT67 cells was used to infect E86 cells followed by G418 selection (1 mg/mL). Prior to transductions, virus was concentrated with PEG-IT (System Biosciences), then re-suspended to equal titers with RPMI complete media. Virus was titered using an NIH3T3 infectivity assay. Briefly, NIH3T3 cells were plated at 0.5 × 10 5 cells/well in a 6-well plate. Cells were transduced with supernatant from virus producing cells at various dilutions, then underwent G418 selection. After 7 days, colonies were counted and viral titer (pfu) determined.
Generating mouse CAR T cell
CD4
+ T cells were isolated from processed C57BL/ 6 spleens by magnetic bead selection and typically had a purity of >90% (Miltenyi, San Diego, CA or MojoSort, Biolegend, San Diego, CA). The CD4 + T cells were activated with plate-bound anti-CD3 and soluble anti-CD28 antibodies at a concentration of 500 ng/mL each for 48 h at 37°C. T cells were transduced with virus to express the B7H6-specific CAR and mouse T-bet, T-bet (STOP), or T-bet (ΔTBOX) constructs through spin transduction, as previously described [40] . Mock T cells were generated to serve as a negative control. Mock T cells are CD4 + T cells which have been transduced with a pFB-neo viral vector which contains no gene construct insertion. Concanavlin A (ConA)-activated CAR T cells were transduced with B7H6-specific CAR retrovirus, as previously described [40] . CAR T cells underwent G418 selection for 3 days at 0.5 mg/mL then histopaque enriched to isolate live cells. Purified CD4 + T cells and ConA-stimulated T cells were cultured in complete RPMI 1640 media with 100 U/mL or 25 U/mL of rIL-2, respectively.
Flow cytometry
Mouse CAR T cells were stained with antibodies for CD3ε (145-2c11 Biolegend), CD4 (Clone GK1.5 Biolegend), and CD8α (clone 53-6.7 Caltag) as previously described [40] . 
In vitro cytotoxicity
Tumor cell lines of RMA, RMA-B7H6, B16F10, and B16F10-B7H6 expressing the PPyre9-GFP gene were plated at 5 × 10 3 cells per well in a 96-well plate. RMA and B16F10 cell lines were plated in round bottom or flat bottom plates, respectively. CAR T cells were added at various T cell effector to target ratios (E:T) of 5:1, 1:1, and 0.2:1. Cells were co-cultured at 37°C for 24 h followed by addition of 50 μL of luciferin (200 μg/mL) (Promega) and incubated at 37°C for 30 min before analyzing luminescence.
Production of B7H6-Fc
Human B7H6-Fc fusion sequence was constructed by fusing the human B7H6 extracellular portion (AA 1-262) with a murine IgG2a hinge-CH2-CH3 portion, then cloned into a pCMV vector. The macaque version of B7H6-Fc was constructed similarly with macaque B7H6 extracellular portion (AA 1-262). The production and purification of B7H6-Fc was performed after transfecting the B7H6-Fc plasmid into 293F cells, as previously described [40] .
Cytokine production
ELISA plates were coated with soluble human B7H6-Fc overnight. Initial concentration started with 100 ng/well followed by fivefold serial dilutions in subsequent wells. Negative control wells were coated with 100 ng of soluble macaque B7H6-Fc. The scFv of the B7H6-specific CAR (TZ47) does not bind to macaque B7H6. Plates were washed the next day with PBS, and 5 × 10 4 CAR T cells were cultured in these wells for 24 h. Cell-free medium was collected and analyzed for IFN-γ production by ELISA.
Total of 1 × 10 5 CAR T cells were co-cultured with RMA, RMA-B7H6, B16F10, or B16F10-B7H6 for 24 h. Cell-free medium was collected and analyzed for cytokine production. IFN-γ was analyzed with a mouse IFN-γ ELISA kit (Biolegend). Production of various cytokines was analyzed with Luminex Multiplex kits (EMD Millipore) through DartLab.
Treatment of tumor-bearing mice with B7H6-specific CAR T cells
Total of 1 × 10 5 RMA-B7H6 cells were injected into mice via the tail vein in 400 μL of HBSS. Seven days later, mice were treated with 2.5 × 10 6 ConA-stimulated T cells expressing the B7H6-specific CAR combined with 5 × 10 6
CD4
+ T cells expressing the B7H6-specific CAR, B7H6-specific CAR/T-bet (ΔTBOX), or Mock CD4 + T cells for a total of 7.5 × 10 6 CAR T cells. Mice were monitored and euthanized upon exhibiting moribund signs or at the end of the experiment.
Experimental designs and statistical analysis
In all in vitro experiments, experimental conditions were run as biological triplicates. Error bars for all experiments represent standard deviations. For in vivo mouse studies, independent experiments consisted of six mice per experimental group and were not intentionally randomized after tumor injection. Investigators were not blinded to the group allocation. Survival data from two independent in vivo mouse studies were combined. The number of independent experiment runs pertaining to each figure is stated within the figure legends. To analyze differences in the mean fluorescence intensity (MFI) of CAR T cells expressing the B7H6-specific CAR or the B7H6-specific CAR/T-bet, paired t -test was used. Student's t -test was used to analyze differences in the multiplex panel between CD4 + T cells expressing the B7H6-specific CAR or the B7H6-specific CAR/T-bet. Analysis of variance (ANOVA) was used to analyze differences between experimental groups comparing Mock CD4 + T cells, or CD4 + T cells expressing the B7H6-specific CAR, B7H6-specific CAR/T-bet, B7H6-specific CAR/T-bet (STOP), and B7H6-specific CAR/Tbet (ΔTBOX). Post hoc analysis using the Dunnett's multiple comparison test was used to assess significance of the B7H6-specific CAR/T-bet constructs expressed in T cells in comparison to T cells expressing the B7H6-specific CAR alone. In vitro cytotoxicity assays also used the Dunnett's multiple comparison test but compared the B7H6-specific CAR constructs to Mock CD4 + T cells. Post hoc analysis using the Tukey's multiple comparison test was used to assess significance between all experimental groups. A Kaplan-Meier plot was used to graph survival and the Logrank Mantel-Cox test was used to assess statistical significance. All statistical analyses were run for two-sided comparisons under the assumption of a normal distribution. Statistical analysis was assessed through GraphPad Prism software (GraphPad Software, San Diego, CA, USA).
Results
Construction of B7H6-specific CAR/T-bet
To create CAR T cells that could modify the tumor microenvironment through Th1 cytokines, a CAR construct was generated that co-expressed a CAR specific for B7H6 with the transcription factor T-bet. The B7H6-specific CAR contains TZ47, a scFv specific for human B7H6, along with a human CD28 hinge, transmembrane, and cytoplasmic domains, followed by a human CD3ζ signaling domain, as previously described [40] . Coexpression of the CAR and T-bet from the same vector was achieved using a T2A containing construct. A T2A sequence was inserted between the B7H6-specific CAR construct and the T-bet transcription factor (Fig. 1a) . Prior to transduction, viruses containing the CAR constructs were concentrated to an equal titer. The expression of the CAR and T-bet after transduction of purified murine CD4 + T cells was assessed by flow cytometry. An overall increase in both CAR expression and T-bet expression was observed in CD4 + T cells transduced with the B7H6-specific CAR/T-bet compared with CD4 + T cells transduced with the B7H6-specific CAR alone (Fig. 1b) . Across three independent experiments, a general trend of increased expression of the CAR and T-bet was observed for T cells expressing B7H6-specific CAR/T-bet than the B7H6-specific CAR alone. Additionally, this increased CAR expression was also observed when total splenic T cells were used, where CD8 + T cells comprised the majority of the cell population (data not shown). 
T-bet overexpression in CD4
+ CAR T cells produce more Th1 cytokines T-bet does not require the T-box region to enhance CD4 + CAR T cells
To assess the extent that the T-box region was important for the effects observed with the B7H6-specific CAR with T-bet, two new constructs were generated where the mouse T-bet gene was modified to remove the T-box region (Fig. 3a) . In one construct, a nonsense mutation was inserted at nucleotide position 214 to create a truncated protein, this construct was designated B7H6-specific CAR/ T-bet (STOP). In the other construct, designated B7H6-specific CAR/T-bet (ΔTBOX), nucleotides 403-978 were deleted, and the remaining DNA sequences were joined. (Fig. 3d) . Against B16F10-B7H6, CD4 + T cells expressing the B7H6-specific CAR/T-bet (ΔTBOX) or the B7H6-specific CAR/T-bet induced cytotoxicity compared to other constructs. CD4 + CAR T cells co-cultured with RMA or B16F10 had comparable RLU to that of the Mock control T cells. This indicated specific killing only when B7H6 is expressed on the tumor cells. In summary, CD4 + CAR T cells co-expressing the B7H6-specific CAR with either T-bet or T-bet (ΔTBOX) can effectively mediate cell killing of tumors expressing B7H6. Because differences in the amount of IFN-γ secretion among CD4 + T cells expressing the B7H6-specific CAR with T-bet variants were observed, we hypothesized that T-bet is specifically modulating CAR T cell function after direct CAR signaling is initiated by receptor-ligand interactions. To elucidate this, ELISA plates were coated with purified B7H6-Fc protein at various concentrations. CD4 + T cells expressing the different CAR constructs were cultured in these plates for 24 h, followed by analysis of the amount of IFN-γ secreted. Unexpectedly, no significant differences were observed in the amount of IFN-γ secreted by these CAR T cells at a concentration of 100 ng/well of B7H6-Fc (Fig. 4a ). Data were compared across multiple experiments to identify whether the co-expression of T-bet can lower the threshold of antigen required to stimulate secretion of IFN-γ by CAR T cells. The amount of antigen needed to stimulate an IFN-γ response for all B7H6-specific CD4 + CAR T cells was similar, based on the average EC 50
values of the dose response curves (Fig. 4b) . Therefore, the data indicate that CD4 + T cells expressing T-bet or T-bet variants had no influence on modulating the response stimulated by the CAR's interaction with the antigen alone. This suggests that T-bet may be enhancing CD4 + effector cell function through pathways independent of the direct signaling pathway triggered by the CAR.
T-bet promotes survival in RMA-B7H6 lymphoma in vivo model
Since CD4 + CAR T cells expressing the T-bet variants had enhanced functional activity against RMA-B7H6, we sought to determine whether CD4 + T cells co-expressing the B7H6-specific CAR/T-bet could enhance CAR T cell efficacy in vivo. The B7H6-specific CAR/T-bet (ΔTBOX) construct was used to investigate the therapeutic potential in vivo as a way to study the enhanced CAR expression and function without the T-bet DNA-binding domain activity. This should mitigate any risks of having unknown gene activation by the T-box DNA-binding domain. CAR T cells were used to treat an established B7H6 lymphoma using the RMA-B7H6 lymphoma mouse model in C57BL/6 mice, which have an intact immune system. RMA-B7H6 cells express human B7H6; however, C57BL/6 mice allow these tumors to grow robustly in vivo [40] . Furthermore, previous work has shown that B7H6-specific CAR T cells originally activated with ConA can eliminate the tumors when multiple CAR T cell doses were used. These ConA CAR T cells are a mixture of~75% CD8 + and 25% CD4 + T cells, as previously characterized [40] . To assess the impact of the CD4 + CAR T cells in treatment of the RMA-B7H6 model, 
Discussion
In this study, the T-bet transcription factor was co-expressed with a CAR to augment the antitumor response generated by CD4 + CAR T cells. T-bet is recognized as the major transcription factor responsible for differentiating T helper CD4 + cells into a Th1 phenotype while simultaneously suppressing Th2 function. CD4 + CAR T cells overexpressing T-bet exhibit this function upon CAR stimulation, producing elevated amounts of IFN-γ, a Th1 designated cytokine directly regulated by T-bet, while reducing secretion of IL-13, a Th2 cytokine, compared to CD4 + T cells expressing the CAR alone. However, IL-2 secretion was increased in CAR T cells upon T-bet coexpression, challenging earlier studies that suggested T-bet inhibits IL-2 secretion [28, 34, 41, 42] . One reason for this discrepancy could be the contribution of the CAR signaling through the CD3ζ activation domain and CD28 costimulatory molecule. Activation of a T cell through the CD28 costimulatory domain has been shown to induce IL-2 secretion, which may override T-bet's role in suppressing IL-2 production. This study revealed that CAR expression increased when T-bet was co-expressed in CD4 + T cells, even though no known T-bet-binding sites are found within the construct. The increase in CAR expression on CD4 + T cells could affect the functional characteristics leading to enhanced cell killing or modification of the threshold for T cell activation. Altering the threshold for T cell activation may have advantages in treating tumors, such as inducing responses against tumors which express low amounts of antigen or decreasing risks of targeting normal cells expressing the antigen. Several studies on T cell stimulation through the T cell receptor (TCR) have shown that a low amount of TCR receptor expression and antigen stimulation is required to induce T cell activation [43, 44] . Additional properties, such as denser clustering of the TCR on the cell membrane or costimulation through CD28 signaling, have been observed to lower the activation threshold [44] . Thus, we attempted to define whether T-bet may be influencing initial stimulation of the CAR T cells by isolating the direct interactions of the CAR ligand (B7H6) with the CAR. T cells expressing T-bet. However, some phenotypic and functional characteristics remained intact upon mutations in T-bet. In particular, CAR expression was still upregulated in CD4 + CAR T cells expressing T-bet with a deleted T-box domain. This suggested that direct binding of T-bet to the DNA through the T-box domain was not required for CAR upregulation, and T-bet may be interacting with other partner proteins via the transactivation domains of T-bet. T-bet is known to interact with different partner proteins, such as NF-ΚB and GATA-3, through its transactivation domains. This enables T-bet to regulate gene expression and cellular functions without directly binding to DNA [28, 34] . T-bet lacking the T-box domain may still complex with these other protein partners, enabling CD4 + CAR T cells to maintain an increased expression of the CAR. Thus, T-bet is multifaceted in its ability to regulate CD4 + CAR T cell characteristics and opens new avenues of research to study these underlying interactions.
Multiple treatments with B7H6-specific CAR T cells have shown efficacy in immunocompetent mice bearing RMA-B7H6 [39, 40] . However, treatment with the addition of CD4 + T cells expressing the B7H6-specific CAR/T-bet (ΔTBOX) improved survival despite tumor-bearing mice being treated with a single injection of these CAR T cells. The combination treatment of the CD8 + T cells expressing the B7H6-specific CAR and the CD4 + T cells expressing the B7H6-specific CAR/T-bet (ΔTBOX) showed an overall increase in median survival time and long-term survivors compared to the control group. This suggests that the improvement in survival was dependent upon the CD4 + T cells expressing the B7H6-specific CAR/T-bet (ΔTBOX), which functions as a mediator of the immune response against the tumor. Additionally, the CD4 + T cells expressing the B7H6-specific CAR/T-bet (ΔTBOX) may be aiding in eliminating the tumor through cytotoxicity mechanisms, such as FAS-FASL interactions, which RMA cell lines are susceptible. In summary, T-bet skewed the response of CD4 + B7H6-specific CAR T cells to secrete more proinflammatory and Th1 cytokines, while reducing the amount of Th2 cytokines when stimulated with B7H6-expressing tumors. The T-box domain of the T-bet gene was not critical for several of the phenotypic and functional differences, rather data suggest it aids in amplifying the CAR T cells' response which has translated into an effective response in a suboptimal treatment against a mouse lymphoma. In conclusion, CAR T cells overexpressing T-bet can be used to enhance CAR T cell therapy against cancer.
